ASX / MEDIA RELEASE **14th April 2016**

RESIRT Study Completes Patient Recruitment

Sydney, Australia; 14th April 2016 – Sirtex Medical Limited (ASX:SRX) is pleased to announce the completion of patient recruitment onto the company's RESIRT study investigating the use of SIR-Spheres® Y-90 resin microspheres for the treatment of primary Renal Cell Carcinoma (RCC, the most common type of kidney cancer).

The RESIRT study is an Australian-based, multi-centre, single arm, dose escalation study in patients with RCC that were not suitable for curative therapy by surgical re-section, ablation or other conventional techniques.

Dr David N. Cade, Sirtex's Chief Medical Officer said "RESIRT represents our first clinical study investigating the use of SIR-Spheres microspheres outside of the liver. While partial or complete surgical removal of the kidney remains the standard treatment approach for primary kidney cancer, we believe SIR-Spheres microspheres may ultimately offer a minimally invasive treatment alternative for patients unable or unwilling to be treated surgically."

According to SEER[1], there were estimated to be 61,560 new cases of kidney cancer in the United States during 2015, representing 3.7% of all cancer cases. Kidney cancer is the 13th most common cancer worldwide, with approximately 338,000 cases globally in 2012[2]. RCC accounts for approximately 90% of all new kidney cancers.

Initial results of the RESIRT study are anticipated to be available during the fourth quarter of calendar year 2016.

About RESIRT

A total of 21 patients were recruited serially into six dose escalating cohorts: 75 Gray (Gy), 100 Gy, 150 Gy, 200 Gy, and 300 Gy of intended radiation dose to tumour. The sixth cohort allowed the delivery of SIR-Spheres microspheres until cessation of blood flow in the renal artery. SIR-Spheres microspheres were administered once only with each patient receiving one allocated radiation dose. The primary endpoint of the study is safety and toxicity at 30 days, with secondary endpoints of tumour response rates, Progression-Free Survival (PFS), Overall Survival (OS) and Quality of Life (QoL). The study is listed on the Australian New Zealand Clinical Trials Registry (ANZCTR) under the identifier ACTRN12610000690055.

Head Office
Level 33, 101 Miller Street
North Sydney, NSW 2060
Australia

Americas
300 Unicorn Park Drive
Woburn, MA 01801
United States

Europe, Middle East & Africa
Josef-Schumpeter-Allee 33
53227 Bonn
Germany

Asia Pacific
50 Science Park Road, #01-01
The Kendall Science Park II
Singapore 117406

About SIR-Spheres® Y-90 Resin Microspheres

SIR-Spheres Y-90 resin microspheres are a medical device used in interventional oncology and delivered to the liver via Selective Internal Radiation Therapy (SIRT). SIR-Spheres Y-90 resin microspheres are approved for supply in key markets, such as the United States, European Union and Australia.

About Sirtex Medical

Sirtex Medical Limited (ASX:SRX) is an Australian-based global healthcare business working to improve outcomes in people with cancer. Our current lead product is a targeted radiation therapy for liver cancer. Approximately 61,000 doses have been supplied to treat patients with liver cancer at more than 950 medical centres in over 40 countries. For more information please visit www.sirtex.com.

For further information please contact:

Investor Enquiries:

Dr David N. Cade
CMO
Sirtex Medical Limited
Phone: +61 (0) 2 9964 8400

Dr Tom Duthy
Global Investor Relations Manager
Sirtex Medical Limited
Phone: +61 (0) 2 9964 8427
Email: tduthy@sirtex.com

Media Enquiries:

Tim Allerton or Andrew Geddes
City PR
Phone: +61 (0) 2 9267 4511

[1] Surveillance, Epidemiology and End Results Program (SEER) of the National Cancer Institute (NCI). http://seer.cancer.gov/statfacts/html/kidrp.html

[2] Cancer Research UK. www.cancerresearchuk.org